Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) (Q24246517)

1

0 references

J D Mitchell

2

0 references

Mary Lyon

3

0 references

Dan H Moore

Cochrane Database of Systematic Reviews

4

0 references

publication date

24 January 2007

0 references

published in

0 references

cites work

A study of riluzole in the treatment of advanced stage or elderly patients with amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001447.PUB2

The effect of riluzole in amyotrophic lateral sclerosis: a study with cortical stimulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001447.PUB2

High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001447.PUB2

Recovery of N-acetylaspartate in corticomotor neurons of patients with ALS after riluzole therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001447.PUB2

Audit of outcomes in motor neuron disease (MND) patients treated with riluzole.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001447.PUB2

An analysis of extended survival in patients with amyotrophic lateral sclerosis treated with riluzole

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001447.PUB2

Riluzole and amyotrophic lateral sclerosis survival: a population-based study in southern Italy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001447.PUB2

Effects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001447.PUB2

ALS therapy: targets for the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001447.PUB2

Relationship of the Tufts Quantitative Neuromuscular Exam (TQNE) and the Sickness Impact Profile (SIP) in measuring progression of ALS. SSNJV/CNTF ALS Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001447.PUB2

The Riluzole Early Access Programme: descriptive analysis of 844 patients in France. ALS/Riluzole Study Group III.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001447.PUB2

Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001447.PUB2

Clinical trials of riluzole in patients with ALS. ALS/Riluzole Study Group-II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001447.PUB2

Practice parameter: the care of the patient with amyotrophic lateral sclerosis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology: ALS Practice Parameters Task Force

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001447.PUB2

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001447.PUB2

Therapeutic horizons for amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001447.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001447.PUB2

El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases a

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001447.PUB2

7 January 2021

Effects of riluzole on symptom progression in amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001447.PUB2

7 January 2021

Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001447.PUB2

7 January 2021

A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001447.PUB2

7 January 2021

Riluzole for the treatment of amyotrophic lateral sclerosis--too soon to tell?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001447.PUB2

7 January 2021

A double-blind, placebo-controlled trial of high doses of gangliosides in amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001447.PUB2

7 January 2021

Practice advisory on the treatment of amyotrophic lateral sclerosis with riluzole: report of the Quality Standards Subcommittee of the American Academy of Neurology

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001447.PUB2

7 January 2021

Prognostic indicators of survival in ALS. ALS CNTF Treatment Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001447.PUB2

7 January 2021

The clinical effectiveness and cost-effectiveness of riluzole for motor neurone disease: a rapid and systematic review

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001447.PUB2

7 January 2021

10.1002/14651858.CD001447.PUB2

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017

PubMed publication ID

17253460

1 reference

Consolidated OpenCitations Corpus – April 2017